Welcome to our dedicated page for Integer Hldgs news (Ticker: ITGR), a resource for investors and traders seeking the latest updates and insights on Integer Hldgs stock.
Integer Holdings Corporation (NYSE: ITGR) is a medical device contract development and manufacturing organization (CDMO) that regularly issues news on its operations, financial performance, and corporate developments. The company focuses on serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets, and its updates reflect activity across these areas.
On this page, readers can follow ITGR news related to quarterly earnings, product line performance, and outlooks that Integer provides through press releases furnished with Form 8-K filings. These releases often include discussions of sales trends in Cardio & Vascular, Cardiac Rhythm Management & Neuromodulation, and Other Markets, along with non-GAAP financial measures such as adjusted operating income, adjusted EBITDA, adjusted net income, and adjusted earnings per share.
Integer’s news flow also covers strategic and governance events, such as leadership transitions, board appointments, and capital allocation decisions. Recent examples include the appointment of a new President and Chief Executive Officer, the election of a new director with extensive medical device industry experience, and the authorization of a share repurchase program by the Board of Directors.
In addition, Integer publishes updates on technology and market-facing activities, such as participation in medical society meetings and healthcare investor conferences. The company has highlighted innovations in neuromodulation and miniaturized active implantable medical devices, including high-performance batteries and integrated implantable pulse generator and lead systems, as well as its Xcellion Gen 3 fast charge lithium ion battery technology.
Investors and observers can use this news page to monitor how Integer communicates its strategy, product line dynamics, financing actions, and role as a CDMO in the cardiac rhythm management, neuromodulation, and cardio and vascular markets.
Summary not available.
Summary not available.
Summary not available.
Integer Holdings Corporation (NYSE:ITGR) reported a strong performance in Q1 2023, with sales increasing 22% to $379 million and organic growth of 21%. GAAP net income rose by $2 million to $13 million, while non-GAAP adjusted net income grew by $3 million to $29 million. GAAP operating income surged 52% to $34 million, and adjusted operating income increased 28% to $50 million. Adjusted EBITDA also saw a 22% rise to $66 million. However, total debt increased by $77 million, reaching $1,002 million, resulting in a leverage ratio of 3.6 times adjusted EBITDA. The company anticipates organic sales growth of 7% to 9% for the full year 2023, with continued margin expansion expected.
Integer Holdings Corporation (NYSE:ITGR) will release its first quarter 2023 financial results on April 27, 2023, at 7 a.m. CT / 8 a.m. ET. Following the earnings release, a conference call will be held at 8 a.m. CT / 9 a.m. ET to discuss the results and any material forward-looking information. Investors can access the call via domestic or international dial-in numbers, with a conference ID of 9252310. Audio replay will be available for seven days. Integer is a leading medical device outsourcing manufacturer, providing innovative technologies across multiple markets.
Integer Holdings Corporation (NYSE:ITGR) will participate in a virtual fireside chat at the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum on March 21, 2023, at 10:30 AM ET. The chat will feature Joe Dziedzic, President and CEO, and Jason Garland, CFO. Interested investors can access the live and archived webcast via the company’s investor relations website. Integer is a leading medical device outsourcing manufacturer, serving various markets including cardiac and orthopedics.
Integer Holdings Corporation (NYSE:ITGR) reported a 19% sales growth in Q4 2022, reaching $372 million, with annual sales up 13% to $1.376 billion. Despite the growth, GAAP income decreased 15% to $17 million in Q4 and 30% to $65 million for the full year. Adjusted net income rose 12% to $37 million in Q4. The company expects 7% to 9% sales growth in 2023, driven by improving operational efficiencies and capacity investments. Debt increased to $925 million, linked to the Aran Biomedical acquisition. Integer remains optimistic about sustained above-market growth despite challenges in the supply chain.
Integer Holdings Corporation (NYSE: ITGR) announced the successful closing of its $500 million convertible senior notes offering, reducing its floating-rate debt. The offering was oversubscribed, increasing from $375 million to $500 million due to strong investor demand. The new 2.125% notes, due 2028, will decrease annual interest expenses by approximately $15 million, enhancing earnings immediately in 2023. The proceeds will repay existing debt, aligning the maturity of the notes with current obligations. The enhanced conversion structure aims to minimize future dilution, with a conversion price at a significant premium to the current stock price.
Integer Holdings Corporation (NYSE: ITGR) will exhibit at the MD&M West Exposition in Anaheim, California, from Feb. 7-9, 2023. At booth #1759, Integer will showcase its end-to-end medical device design, development, and manufacturing solutions, enhanced by the acquisitions of Aran Biomedical and Oscor. Key innovations include the new Gen 2 CFx Battery Technology, advanced electrophysiology solutions, and a comprehensive suite of neurovascular and structural heart capabilities. President Payman Khales emphasized the company’s focus on expanding its global footprint and capabilities to meet rising customer demand.
Integer Holdings Corporation (NYSE: ITGR) has announced the pricing of $435 million in 2.125% convertible senior notes due 2028, up from an initial size of $375 million. The offering, set to close on February 3, 2023, comes with an option for purchasers to acquire an additional $65 million. The net proceeds, estimated at $422.2 million, will primarily be used to pay off existing borrowings and expenses associated with capped call transactions valued at $30.5 million. The conversion price of $87.20 per share reflects a 32.5% premium over the January 31 closing price of $65.81. This move aims to reduce exposure to floating rate debt.
FAQ
What is the current stock price of Integer Hldgs (ITGR)?
What is the market cap of Integer Hldgs (ITGR)?
